Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer

  title={Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential I$\kappa$B kinase $\beta$ inhibitors for the treatment of pancreatic cancer},
  author={Xuemeng Xie and Jinfu Tu and Heyi You and Bingren Hu},
  journal={Drug Design, Development and Therapy},
  pages={1439 - 1451}
Given the important role that inhibitory kappa B (IκB) kinase β (IKKβ) plays in pancreatic cancer (PC) development and progression, inhibitors targeting IKKβ are believed to be increasingly popular as novel anti-PC therapies. Two synthetic molecules, named EF24 and EF31, exhibited favorable potential in terms of inhibition of both IKKβ activity and PC cell proliferation. Aiming to enhance their cellular efficacy and to analyze their structure–activity relationship, four series of EF24 and EF31… Expand
Bioactivities of EF24, a Novel Curcumin Analog: A Review
This review summarizes the known biological and pharmacological activities and mechanisms of action of EF24 and shows more potent bioactivity, including anti-cancer, anti-inflammatory, and anti-bacterial. Expand
Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells
This study found that BBM synergizes with Gefi to inhibit cell growth and induce cell cycle arrest and PC cell apoptosis and suggests that the combination of BBM andGefi could be further developed as a potential PC therapy. Expand
Small molecule inhibitors of IκB kinase β: A chip-based screening and molecular docking simulation.
The enzyme-based assay showed that IC50 of the four inhibitors is comparable with that of IKK-16, a previously known strong inhibitor, and the MM-PBSA calculation suggests that these hydrophobic interactions appear to be the predominant contributor to the binding free energy. Expand
Emodin Reverses Gemcitabine Resistance of Pancreatic Cancer Cell Lines Through Inhibition of IKKβ/NF-κB Signaling Pathway
Emodin inhibits the expression of IKKβ, thereby inhibiting the expression and activity of downstream NF-κB, and inhibits P-gp function at the same time, ultimately achieving the purpose of reversing the drug-resistance of pancreatic cancer cell lines. Expand
Chloro and bromo-pyrazole curcumin Knoevenagel condensates augmented anticancer activity against human cervical cancer cells: design, synthesis, in silico docking and in vitro cytotoxicity analysis
Chloro derivative and bromo analog must be evaluated under a set of stringent in vitro and in vivo parameters for translating in to a clinically viable product. Expand
Design and synthesis of methoxyphenyl- and coumarin-based chalcone derivatives as anti-inflammatory agents by inhibition of NO production and down-regulation of NF-κB in LPS-induced RAW264.7 macrophage cells.
Among the 18 synthesized chalcone derivatives, compound 2f exhibited the highest anti-inflammatory activity by inhibition of nitric oxide concentration in LPS-induced RAW264, and docking studies suggested the inhibition of IKKβ as a mechanism of action and highlighted the importance of 2f hydrophobic interactions. Expand
Hybridization of Curcumin Analogues with Cinnamic Acid Derivatives as Multi-Target Agents Against Alzheimer’s Disease Targets
The synthesis of the new hybrids followed a hybridization with the aid of hydroxy-benzotriazole and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide in dry DMF or thionyl chloride between curcumin analogues and cinnamic acid derivatives to propose a possible mechanism of action. Expand
Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases
This work focuses on molecular targeting of Cur to reduce amyloid burden, rescue neuronal damage, and restore normal cognitive and sensory motor functions in different animal models of neurodegenerative diseases. Expand
Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review
The pharmacological effects ofCurcumin against GI cancers is summarized and the application of curcumin's analogues and novel delivery systems in the treatment of GI cancers are highlighted. Expand


Recent advances in the structure-based and ligand-based design of IKKβ inhibitors as anti-inflammation and anti-cancer agents.
This review focuses on two parts: the chemotypes and binding patterns of the traditional ATP-competitive IKK inhibitors; and novel strategies for the identification of non-ATP- competitive IKK inhibitor as NF-κB modulators. Expand
Inhibition of IκB Kinase-Nuclear Factor-κB Signaling Pathway by 3,5-Bis(2-flurobenzylidene)piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin
The study identifies IKK as an effective target for EF24 and provides a molecular explanation for a superior activity of EF24 over curcumin, and extends the therapeutic application ofEF24 to other NF-κB-dependent diseases, including inflammatory diseases such as rheumatoid arthritis. Expand
Targeting the NF-κB and mTOR Pathways with a Quinoxaline Urea Analog That Inhibits IKKβ for Pancreas Cancer Therapy
Results show that 13-197 is orally available with extensive distribution to peripheral tissues and inhibited tumor growth and metastasis in an orthotopic pancreatic cancer model without any detectable toxicity. Expand
Hit identification of IKKβ natural product inhibitor
A benzoic acid derivative is identified as a novel IKKβ inhibitor via high-throughput molecular docking and was able to inhibit IKK β phosphorylation activity in vitro, and block IκBα protein degradation and subsequent NF-κB activation in human cells. Expand
Apigenin potentiates the growth inhibitory effects by IKK-β-mediated NF-κB activation in pancreatic cancer cells.
Results indicated that apigenin had a potential to inhibit IKK-β-mediated NF-κB activation, and was a valuable agent for the pancreatic cancer treatment. Expand
Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties.
EF31 represents a promising curcumin analog for further therapeutic development and demonstrated potent toxicity in NF-κB-dependent cancer cell lines while having minimal and reversible toxicity in RAW264.7 macrophages. Expand
Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer.
Results were observed in vitro when subcutaneous tumors (MiaPaCa-2) were treated with EF31 and UBS109 and inhibited HSP-90 and NF-κB leading to downregulation of DNA methyltransferase-1 (DNMT-1) expression. Expand
Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-κB in BxPC-3 Pancreatic Cancer Cell Line
Genistein pretreatment, which inactivates NF-κB activity, together with other cellular effects of genistein, may contribute to increased cell growth inhibition and apoptosis inducing effects of nontoxic doses of docetaxel and cisplatin, which could be a novel strategy for the treatment of pancreatic cancer. Expand
Inhibitory kappa B kinases as targets for pharmacological regulation
The impact of small molecule inhibitors of IKK catalytic activity will be reappraised, examining the advantages and potential disadvantages to this type of intervention strategy in the treatment of diseases such as arthritis, intestinal inflammation and cancer. Expand
The Role of Nuclear Factor &kgr;B in Pancreatic Cancer and the Clinical Applications of Targeted Therapy
Evidence that different NF-&kgr;B-inhibiting drugs can improve the treatment of pancreatic cancer is examined and the roles of NF-JB in these processes are explored. Expand